Apart from the expression of PD-L1 and TMB, there are some specific gene mutations including KRAS/TP53, STK11, EGFR, EPHA, and NOTCH, that are related to efficacy of ICIs by regulating the tumor microenvironment and served as potential biomarkers to predict the clinical benefits of immunotherapy [24–27]. Here, EGFR is linked to neoplasm.